Results 141 to 150 of about 25,220 (171)
Some of the next articles are maybe not open access.
Comprehensive Review on Ebola (EBOV) Virus: Future Prospects
Infectious Disorders - Drug Targets, 2018Ebola virus (EBOV) was discovered for the first time in 1976. It belongs to the family Filoviridae, which causes hemorrhagic fever that could lead to death in a few days. West Africa faced a major outbreak where symptoms appeared in the form of chills, myalgia, fever, diarrhea, and vomiting, and the disease finally reached a severe state as a result of
Haroon Khan +2 more
exaly +3 more sources
Quantifying the epidemic spread of Ebola virus (EBOV) in Sierra Leone using phylodynamics [PDF]
Virulence, 2014 Measuring epidemic parameters early in an outbreak is essential to inform control efforts. Using the viral genome sequence and collection date from 78 infections in the 2014 Ebola virus outbreak in Sierra Leone, we estimate key epidemiological parameters such as infectious period duration (approximately 71 hours) and date of the first case in Sierra ...
Samuel Alizon +2 more
exaly +4 more sources
Open-label phase I clinical trial of Ad5-EBOV in Africans in China [PDF]
Human Vaccines and Immunotherapeutics, 2017 To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China.A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 participants receiving one shot intramuscular injection and 30 participants ...
Nanping Wu, Pei Liu, Yao Hp
exaly +4 more sources
Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus–Infected Rhesus Macaques
Journal of Infectious Diseases, 2023Abstract Vesicular stomatitis virus–Ebola virus (VSV-EBOV) vaccine has been successfully used in ring vaccination approaches during EBOV disease outbreaks demonstrating its general benefit in short-term prophylactic vaccination, but actual proof of its benefit in true postexposure prophylaxis (PEP) for humans is missing.
Heinz Feldmann +2 more
exaly +3 more sources
Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV
Vaccine, 2018VSV-EBOV is a replication-competent Ebola virus (EBOV) vaccine, which was tested in clinical trials as response to the Ebola virus disease (EVD) outbreak 2013-2016. It is the most advanced EBOV candidate currently in the licensure process. The experimental vaccine was again administered as response to outbreaks in the Democratic Republic of Congo ...
S Schmiedel, A W Lohse
exaly +3 more sources
Usp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV [PDF]
Vaccines, 2020 Ebola virus epidemics can be effectively limited by the VSV-EBOV vaccine (Ervebo) due to its rapid protection abilities; however, side effects prevent the broad use of VSV-EBOV as vaccine. Mechanisms explaining the efficient immune activation after single injection with the VSV-EBOV vaccine remain mainly unknown.
Judith Lang, Karl Lang, Kenichi Asano
exaly +10 more sources
Development and evaluation of a real-time EBOV-L-RT-qPCR for detection of Zaire ebolavirus
Journal of Clinical Virology, 2015An RT-qPCR targeting EBOV-L including the preceding RNA extraction protocol were set up and evaluated.
Kirsi Johanna Aaltonen +2 more
exaly +3 more sources
Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient [PDF]
Eurosurveillance, 2015 Binary file ES_Abstracts_Final_ECDC.txt matches
Tom Decroo +2 more
exaly +4 more sources
Small‐Molecule Therapeutics for Ebola Virus (EBOV) Disease Treatment
European Journal of Organic Chemistry, 2015AbstractThe current epidemic of Ebola virus (EBOV) hemorrhagic fever in sub‐Saharan West‐African countries, in terms of severity, is second only to the human immunodeficiency virus (HIV). Besides the strong pathogenicity of EBOV, the unprecedented fatality rates (up to 90 %) are partially the result of a near total absence of any proper vaccines and ...
Kunisuke Izawa +4 more
openaire +1 more source
ChemInform Abstract: Small‐Molecule Therapeutics for Ebola Virus (EBOV) Disease Treatment
ChemInform, 2016AbstractReview: [discovery, synthesis, and modes of action of three antiviral compounds currently in development against Ebola virus (EBOV) infection; 40 refs.
Kunisuke Izawa +4 more
openaire +1 more source